| Ytd | 46.49% | |
| 1y | 27.83% |
| Open | 2.73 | Prev Close | 2.76 | Low | 2.65 | High | 2.75 | Mkt Cap | 194.10M |
| Vol | 478.17K | Avg Vol | 653.81K | EPS | -1.59 | P/E | N/A | Forward P/E | -1.42 |
| Beta | 0.87 | Short Ratio | 5.44 | Inst. Own | 99.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 2.62 | 200-d Avg | 2.42 | 1yr Est | 15.83 |
Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price targ
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consens
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Paris, France and New York, USA,
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at t
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indica
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five
Mizuho analyst Salim Syed maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price t
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which missed the analyst consens
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
Nkarta (NASDAQ: NKTX - Get Free Report) and Bolt Biotherapeutics (NASDAQ: BOLT - Get Free Report) ar
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
AWM Investment Company Inc. trimmed its position in shares of Nkarta, Inc. (NASDAQ: NKTX) by 30.0% d
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
Nkarta Inc. remains a compelling buy as it pivots its NK cell therapy pipeline toward autoimmune dis
Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price targ
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all pati
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinic
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmun
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company report
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted a
On Monday, 369 companies set new 52-week lows.
Friday's session saw 112 companies set new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Thursday, 109 companies set new 52-week lows.
Wednesday's session saw 43 companies set new 52-week lows.
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company
On Wednesday, 220 stocks hit new 52-week lows.